Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 786

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 4
Chunk 786
---
 Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  
    32.2**
     
    Certification of Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  
    97.1
     
    Denali Capital Acquisition Corp. Policy on Recoupment of Incentive Compensation, dated as of November 28, 2023(13)
  
    101.INS
     
    Inline XBRL Instance Document.
  
    101.SCH
     
    Inline XBRL Taxonomy Extension Schema Document.
  
    101.CAL
     
    Inline XBRL Taxonomy Extension Calculation Linkbase Document.
  
    101.DEF
     
    Inline XBRL Taxonomy Extension Definition Linkbase Document.
  
    101.LAB
     
    Inline XBRL Taxonomy Extension Label Linkbase Document.
  
    101.PRE
     
    Inline XBRL Taxonomy Extension Presentation Linkbase Document.
  
    104
     
    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed
herewith

**Furnished
herewith

36

#Certain
of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). Denali Capital Acquisition
Corp. agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

^Certain
identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material
and (ii) information that the Registrant treats as private or confidential. Denali Capital Acquisition Corp. hereby undertakes to furnish
supplemental copies of the unredacted exhibit upon request by the SEC.

(1)Filed
as an exhibit to Amendment No. 1 to the Registration Statement on Form S-1 filed with the SEC on March 22, 2022 (File No. 333-263123).

(2)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on April 12, 2022 (File No. 001-41351).

(3)Filed
as an exhibit to the Current